Bortenat Injection (3.5mg), which contains the active ingredient Bortezomib, is a potent medication primarily used in the treatment of multiple myeloma and certain types of lymphoma. This injectable formulation is designed to inhibit the proteasome, a cellular complex responsible for degrading unneeded or damaged proteins, thereby disrupting the cancer cell cycle and promoting apoptosis, or programmed cell death. Bortenat Injection is typically administered under the supervision of a healthcare professional, ensuring that patients receive the correct dosage and monitoring for any potential side effects. The composition of Bortenat includes Bortezomib, which is a boronic acid derivative, and is often combined with other therapeutic agents to enhance its efficacy. This drug plays a crucial role in modern oncology, offering hope to patients battling these challenging malignancies.

Velcade Injection (3.5mg), containing the active ingredient Bortezomib, is a potent medication primarily used in the treatment of multiple myeloma and certain types of lymphoma. This injectable drug works by inhibiting the proteasome, a cellular complex responsible for degrading unneeded or damaged proteins, thereby disrupting the cancer cell cycle and promoting apoptosis, or programmed cell death. Velcade is typically administered via subcutaneous or intravenous injection, allowing for effective absorption and rapid action within the body. The formulation of Velcade Injection is designed to deliver a precise dosage of 3.5mg of Bortezomib, ensuring that patients receive the appropriate amount for optimal therapeutic effect. As a targeted therapy, Velcade plays a crucial role in modern oncology, offering hope to patients battling these challenging malignancies.